Meeting
2015 ASCO Annual Meeting
A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
Authors
Frédéric Selle
Medical Oncology, Hôpital Tenon, Paris, France
Frédéric Selle , Anne Lesoin , Marie-Christine Kaminsky , Philippe Follana , Isabelle Ray-Coquard , Dominique Berton-Rigaud , Anne Floquet , Anne-Claire Hardy-Bessard , Florence Joly , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01111903
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5530)
DOI
10.1200/jco.2015.33.15_suppl.5530
Abstract #
5530
Poster Bd #
88
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of non-pegylated liposome-encapsulated doxorubicin citrate (NPLD) plus carboplatin in patients with recurrent gynecological and primary peritoneal tumors.
First Author: Andres Poveda
Poster
2015 ASCO Annual Meeting
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).
First Author: Feriel Boumedien
Poster
2022 ASCO Annual Meeting
Efficacy and toxicity of carboplatin and gemcitabine dosed on day 1/day 8 versus day 1 alone for platinum-sensitive recurrent epithelial ovarian cancer.
First Author: Erika Joelle Lampert
Poster
2016 ASCO Annual Meeting
Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.
First Author: Jonathan Foote